Peptide fact checks.

FDA's identity record lists GHRP-6 as a hexapeptide, which means six amino acids, and gives its sequence. An identity record does not prove approval, quality, or equivalence between products.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

The FDA-identified GHRP-6 molecule only. This identity fact does not cover every product sold under the name.

Small studies in healthy men measured short-term increases in growth hormone after GHRP-6. One study found that the response depended in large part on GHRH, another body signal. These are hormone measurements, not proof of treatment benefit.

What this answer is based on

Studies of body changes in people
This answer uses a study of how the substance enters or changes the body in people. This alone does not show a health benefit.

Applies to

Small, short studies in healthy men; hormone response only, not muscle, fat loss, recovery, or other health outcomes.

A hormone response is not the same as a lasting health outcome. The reviewed human studies did not establish muscle gain or fat loss.

What this answer is based on

No reliable studies showing this health result in people
No reliable study in people shows the health outcome in this statement.

Applies to

Muscle, fat-loss, and other lasting outcomes; the reviewed studies measured hormones or exposure only.

No FDA-approved human GHRP-6 product was identified in the checked U.S. databases as of August 30, 2026. FDA's substance identity record does not mean approval. This is a dated database finding, not a claim about every country or future record.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

U.S. human drug records checked on August 30, 2026.

FDA says it does not approve compounded drugs. Its current 503A list puts GHRP-6 in Category 3. This means the nomination did not have enough support. FDA also lists safety concerns for 503B compounding. A 2019 warning letter said GHRP-6 did not meet the 503A rules in that case.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

U.S. FDA records about compounded GHRP-6, checked August 30, 2026. This is not legal advice about one product.

The 2026 WADA Prohibited List names GHRP-6 under growth hormone-releasing factors. WADA prohibits it at all times, both in and out of competition.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

Athletes subject to the 2026 WADA Prohibited List; rules can differ by sport and organization.

FDA describes TB-500 as a seven-amino-acid fragment of the much larger thymosin beta-4 molecule.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

Chemical identity, not a claim about all possible biological activity.

The FDA evidence review did not identify adequate human outcome evidence for wound-healing use.

What this answer is based on

No reliable studies showing this health result in people
No reliable study in people shows the health outcome in this statement.

Applies to

Clinical tendon, muscle, and wound-healing outcomes in people.

TB-500 is named on the current WADA Prohibited List.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

Sport governed by the World Anti-Doping Code.

Yes, but the cited topical trial had 13 completers, found no significant objective improvement in erythema, wrinkles, or skin quality, and reported higher patient satisfaction. It does not establish broader outcomes or other routes.

What this answer is based on

Health results from a study with randomly assigned groups
This answer uses a study that assigned people to groups by chance and measured a health outcome.

Applies to

A specific topical copper-tripeptide formulation after CO2 laser resurfacing.

Route, formulation, exposure, product quality, and endpoint differ. Evidence cannot be transferred by ingredient name alone.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

Topical study formulations versus compounded injectable products.

FDA identifies limited human data and potential immunogenicity related to aggregation and peptide impurities.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

Compounded injectable GHK-Cu.

Preclinical metabolic findings are a real research signal, but they remain preclinical.

What this answer is based on

Cell, animal, or other lab research
This answer uses research in cells, animals, or other settings outside patient care. It does not show a benefit in people.

Applies to

Laboratory and animal research, not patient outcomes.

FDA found no published human drug-product administration studies in its 2026 review.

What this answer is based on

No reliable studies showing this health result in people
No reliable study in people shows the health outcome in this statement.

Applies to

Clinical weight outcomes from administered MOTS-c drug products.

FDA's substance registry explicitly states that UNII availability does not imply regulatory review or approval.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

Substance identification versus drug-product approval.

FDA's review describes several human studies, primarily using oral or intravenous routes.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

Historical study products and routes described in FDA's review.

Exposure and tolerability data do not establish a clinically meaningful weight-loss outcome.

What this answer is based on

No reliable studies showing this health result in people
No reliable study in people shows the health outcome in this statement.

Applies to

Weight-loss efficacy, not merely participation in a study.

FDA identifies limited safety data, immunogenicity concerns, and missing information for proposed injectable use.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

Compounded injectable AOD-9604.

A 2025 laboratory study reported telomere-length effects in cultured human cell lines.

What this answer is based on

Cell, animal, or other lab research
This answer uses research in cells, animals, or other settings outside patient care. It does not show a benefit in people.

Applies to

Cultured cell lines, not health outcomes in treated people.

FDA did not identify clinical insomnia studies of the nominated epitalon substances by the proposed route.

What this answer is based on

No reliable studies showing this health result in people
No reliable study in people shows the health outcome in this statement.

Applies to

Adults with insomnia assessed using clinical sleep outcomes.